Target-Binding Prodrug Composition for Site-Specific Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing prodrugs lack the ability to specifically target drug molecules to target cells and sites while minimizing toxicity, which affects their efficacy and safety profile.
Innovation Solution
Development of prodrugs with cleavable moieties that include specific binding capabilities to target sites, utilizing linker moieties and therapeutic moieties such as amino acids or peptides, allowing for targeted delivery and release of active drugs through enzymatic or intramolecular cyclization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prodrugs are designed to improve drug delivery, then efficacy is enhanced, but specificity and targeting capability deteriorate
Solution Approach 1:
The prodrug is divided into distinct functional segments: a therapeutic moiety (Z) providing the pharmacological effect, a linker moiety (L) enabling targeted delivery, and a cleavable moiety (A) allowing specific release. This segmentation enables each component to perform its specialized function, resolving the contradiction between overall efficacy and targeting precision by ensuring the drug only activates at the intended site.
Solution Approach 2:
The linker moiety acts as an intermediary between the therapeutic moiety and the cleavable moiety, facilitating targeted delivery to specific cells or tissues. This intermediary structure enables the prodrug to navigate biological barriers and reach the target site before activation, thereby improving both efficacy through enhanced delivery and specificity through localized action.
2Object-affected harmful factors
If prodrugs are used to reduce toxicity, then side effects are minimized, but targeting capability to specific cells deteriorates
Solution Approach 1:
The prodrug design implements local quality by concentrating the active therapeutic effect specifically at the target site through the cleavable moiety's site-specific activation. The toxic or active form of the drug is only generated where needed, while the prodrug form circulates safely throughout the body. This localized activation resolves the contradiction by minimizing systemic toxicity while maximizing targeting capability to specific cells or tissues.
3Object-affected harmful factors
If cleavable moieties are added for targeted release, then safety is improved, but device complexity increases
Solution Approach 1:
The prodrug constitutes a composite molecular structure combining the therapeutic moiety, linker moiety, and cleavable moiety into a single integrated molecule. This composite approach allows all functional elements to work together synergistically, improving safety through targeted release while managing complexity by consolidating multiple functions into one molecular entity rather than requiring separate delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the specificity and safety of drug delivery by ensuring targeted release of therapeutic agents at the desired sites, thereby improving efficacy and reducing side effects.
Implementation Method 1
capable of undergoing an intramolecular cyclization to release the therapeutic moiety
Implementation Method 2
capable of undergoing an intramolecular cyclization to release the therapeutic moiety
Data Source
AI summary
Prodrugs including cleavable moieties capable of specific binding to a target are presented. Related pharmaceutical compositions and methods are also presented.